Date: August 13, 2026

To, The Manager, Listing Department, **National Stock Exchange of India Limited (NSE),** Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051.	To, The Department of Corporate Service, **BSE Limited,** 1st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001.
Symbol – LINCOLN	**Scrip Code – 531633**

Dear Sir,

SUB.: OUTCOME OF BOARD MEETING.

Further to our intimation dated August 06, 2026, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we would like to inform that the Board of Directors of the Company at its meeting held today i.e. on Thursday, August 13, 2026, have considered/approved/recommended, inter alia, the followings: -

1. The un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2026 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter ended on June 30, 2026. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, we enclose herewith financial highlights for the aforesaid quarter.

Meeting of the Board of Directors commenced at 10:30 and concluded at 11:30 A.M. Kindly take the same on your records.

Thanking you,
Yours faithfully,

For Lincoln Pharmaceuticals Limited

LINCOLN PHARMACEUTICALS LTD. AHMEDABAD

Trusha Shah
Company Secretary & Compliance Officer
Encl: A/a

Regd. Office : "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.
Phone : +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India
Phone : +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.
CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,
Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter Ended on 30-June-2026.

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026 (Un-Audited)	31/03/2026 Refer No. 3	30/06/2025 (Un-Audited)	31/03/2026 (Audited)
1	**Income**				
	A) Revenue From Operations	17,728.21	18,727.73	15,406.67	67,102.99
	B) Other Income	2,426.46	(419.53)	1,527.17	3,345.40
	Total Income (1)	**20,154.67**	**18,308.20**	**16,933.84**	**70,448.39**
2	**Expenses**				
	A) Cost of Material Consumed	5,857.86	7,372.58	6,096.93	23,957.41
	B) Purchase of Stock-In-Trade	2,093.36	1,644.69	1,583.06	7,902.55
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	563.09	(110.23)	(741.56)	(743.96)
	D) Employee Benefits Expenses	3,331.03	3,245.79	3,175.68	12,518.86
	E) Finance Costs	25.87	27.43	20.98	101.29
	F) Deprecation and Amortisation Expense	388.43	368.28	347.72	1,449.96
	G) Other Expenses	3,139.65	4,089.40	2,912.11	13,699.78
	Total Expenses (2)	**15,399.29**	**16,637.94**	**13,394.92**	**58,885.89**
3	**Profit / (Loss) Before Exceptional Items & Tax (1-2)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
4	Exceptional Items	Nil	Nil	Nil	Nil
5	**Profit / (Loss) after Exceptional items but Before Tax (3-4)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
6	Tax Expense				
	A) Current Tax	535.30	861.90	412.30	2,737.10
	B) Deferred Tax	596.63	(360.98)	359.10	(3.09)
	C) Short / (Excess) Tax Provision	Nil	5.88	Nil	39.11
7	**Net Profit / (Loss) For The Period (5-6)**	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
8	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	41.88	160.63	2.29	167.50
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
9	**Total Comprehensive Income**	**3,665.33**	**1,324.09**	**2,769.81**	**8,956.88**
10	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
11	Other Equity				73,760.23
12	**Earnings Per Share (of Rs. 10/- Each) (Not Annualised)**				
	(a) Basic	18.09	5.81	13.82	43.88
	(b) Diluted	18.09	5.81	13.82	43.88

NOTES:

1. The above unaudited standalone financial results of the Company for the quarter ended June 30, 2026 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 13, 2026. The auditor have carried out an limited review of the said financial results.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The figures for the quarter ended March 31, 2026 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited

LINCOLN PHARMACEUTICALS LTD.

MGPatel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 13, 2026

SAMIR M. SHAH & ASSOCIATES
Chartered Accountants

"Heaven", 8, Western Park Society, Nr. TRP Mall,
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032 E-mail : samir@smshah.co.in

Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors of,
Lincoln Pharmaceuticals Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended June 30, 2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

   The Statement includes the results for the quarter ended 31st March 2026 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited year-to-date figures upto 31stDecember 2025 which were subjected to a limited review.

2. **Management's Responsibility for the statement:**
   This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. **Auditor's Responsibility:**
   We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

SAMIR M. SHAH & ASSOCIATES
PARTNER
FRN
122377W
CHARTERED ACCOUNTANTS

4. **Conclusion:**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Samir M Shah & Associates
Chartered Accountants
(Firm's Registration No. 122377W)

Place: Ahmedabad
Date: 13/08/2026

SAMIR M. SHAH & ASSOCIATES PARTNER FRN 122377W CHARTERED ACCOUNTANTS

Samir Shah

(Samir M. Shah)
Partner
[M. No. 111052]
UDIN: 26111052CPGFGU4877

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.
CIN: L24230GJ1995PLC024288, **Ph. No.:** +91-79-4107-8000,
Website: www.lincolnpharma.com, **E-Mail:** investor@lincolnpharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter Ended on 30-June-2026.

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30/06/2026 (Un-Audited)	31/03/2026 Refer No. 3	30/06/2025 (Un-Audited)	31/03/2026 (Audited)
1	**Income**				
	A) Revenue From Operations	17,728.21	18,727.73	15,406.67	67,102.99
	B) Other Income	2,426.46	(419.53)	1,527.17	3,345.40
	Total Income (1)	**20,154.67**	**18,308.20**	**16,933.84**	**70,448.39**
2	**Expenses**				
	A) Cost of Material Consumed	5,857.86	7,372.58	6,096.93	23,957.41
	B) Purchase of Stock-In-Trade	2,093.36	1,644.69	1,583.06	7,902.55
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	563.09	(110.23)	(741.56)	(743.96)
	D) Employee Benefits Expenses	3,331.03	3,245.79	3,175.68	12,518.86
	E) Finance Costs	25.87	27.44	20.98	101.30
	F) Deprecation and Amortisation Expense	388.43	368.28	347.72	1,449.96
	G) Other Expenses	3,139.65	4,089.39	2,912.11	13,699.77
	Total Expenses (2)	**15,399.29**	**16,637.94**	**13,394.92**	**58,885.89**
3	**Profit / (Loss) Before Exceptional Items & Tax (1-2)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
4	Exceptional Items	Nil	Nil	Nil	Nil
5	**Profit / (Loss) after Exceptional items but Before Tax (3-4)**	**4,755.38**	**1,670.26**	**3,538.92**	**11,562.50**
6	Tax Expense				
	A) Current Tax	535.30	861.90	412.30	2,737.10
	B) Deferred Tax	596.63	(360.98)	359.10	(3.09)
	C) Short / (Excess) Tax Provision	Nil	5.88	Nil	39.11
7	**Net Profit / (Loss) For The Period (5-6)**	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
8	Attributable to Non-Controlling Interest	Nil	Nil	Nil	Nil
	Atributable to Owners of the Company	**3,623.45**	**1,163.46**	**2,767.52**	**8,789.38**
9	Other Comprehensive Income (Net Of Tax)				
	Items that will not be reclassified to subsequently to profit and loss	41.88	160.63	2.29	167.50
	Items that will be reclassified subsequently to profit or loss	Nil	Nil	Nil	Nil
10	**Total Comprehensive Income**	**3,665.33**	**1,324.09**	**2,769.81**	**8,956.88**
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,002.97	2,002.97	2,002.97	2,002.97
12	Other Equity				73,760.23
13	**Earnings Per Share (of Rs. 10/- Each) (Not Annualised)**				
	(a) Basic	18.09	5.81	13.82	43.88
	(b) Diluted	18.09	5.81	13.82	43.88

NOTES:

1. The above unaudited consolidated financial results of the Company for the quarter ended June 30, 2026 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, August 13, 2026. The auditor have carried out an limited review of the said financial results.
2. This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. The figures for the quarter ended March 31, 2026 is the balancing figure between audited figures in respect of the full financial year and for the period upto the end of the third quarter of relevant financial year.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
6. Consolidated Results includes results of its subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited

LINCOLN PHARMACEUTICALS LTD.

MyPatel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 13, 2026

SAMIR M. SHAH & ASSOCIATES

Chartered Accountants

"Heaven", 8, Western Park Society, Nr. TRP Mall,
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032 E-mail : samir@smshah.co.in

Limited Review Report on consolidated un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To the Board of Directors of,
Lincoln Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Lincoln Pharmaceuticals Limited**("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended(the "Listing Regulations").

   The Statement includes the results for the quarter ended 31st March 2026 being the derived figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited year-to-date figures up to 31st December 2025 which were subjected to a limited review.

2. **Management's Responsibility for the statement:**
   This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. **Auditor's Responsibility:**
   We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

SAMIR M. SHAH & ASSOCIATES
PARTNER
FRN
122377W
CHARTERED ACCOUNTANTS

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

A. Lincoln Pharmaceuticals Limited	-	Parent Company
B. Zullinc Healthcare LLP	-	Wholly-Owned Subsidiary Company

5. **Conclusion:**

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the branch auditors and other auditors referred to in paragraph 6 below, nothing has come to our attention that causes usto believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. **Other Matter:**

We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflects total revenues of Rs.Nil Lakhs, total net loss after tax of Rs.Nil Lakhs, for the quarter ended June 30, 2026, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

According to the information and explanations given to us by the Management, above financial results are not material to the Group. Our conclusion on the Statement, in so far as it relates to the amounts included in respect of these subsidiaries, is based solely on the information and explanations given to us by the Management.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

For, Samir M Shah & Associates
Chartered Accountants
(Firm's Registration No. 122377W)

Place: Ahmedabad
Date: 13/08/2026

SAMIR M. SHAH & ASSOCIATES
PARTNER
FRN
122377W
CHARTERED ACCOUNTANTS

Samir Shah

(Samir M. Shah)
Partner
[M. No. 111052]
UDIN: 26111052NWBPYK5062

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Media Release

Lincoln Pharmaceuticals Ltd Reports Consolidated Net Profit of Rs. 36.23 crore in Q1 FY27, growth of 30.90% Y-o-Y

- EBITDA in Q1FY27 up 32.29 % Y-o-Y to Rs. 51.70 crore;
- Total Income in Q1FY27 up 19.02% Y-o-Y to Rs. 201.55 crore

Business Highlights:

- *Targeting Rs. 1,000 crore revenue over the next three year; Aims to achieve 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments*
- *Exports to 60+ countries across key global markets, with plans to expand presence to 90 countries over the next 2-3 years, supported by entry into Canada and EU GMP and TGA Australia approvals.*
- *Developed 600+ formulations across 15 therapeutic areas, with 1,700+ registered products and 700 products under development.*
- *Company remains net-debt free; FII holding in the company as on 30 June 2026 at 4.60%*
- *Crisil Ratings has reaffirmed its 'Crisil A/Stable/Crisil A1' ratings on the bank facilities of the company*

Financial Highlights (Consolidated)

(Amount in Cr except EPS)

Particulars	Q1 FY27	Q1 FY26	Y-O-Y (%)	FY26	FY25	Y-O-Y (%)
Total Income	201.55	169.34	**19.02%**	704.48	645.71	**9.10%**
EBITDA	51.70	39.08	**32.29%**	131.14	123.97	**5.78%**
Profit before Tax	47.55	35.39	**34.36%**	115.63	109.19	**5.90%**
Net Profit	36.23	27.68	**30.90%**	87.89	82.35	**6.74%**
E.P.S (Rs.)	18.09	13.82	**30.90%**	43.88	41.11	**6.74%**

Ahmedabad, 13th August, 2026 : Lincoln Pharmaceuticals Ltd (BSE: 531633 | NSE: LINCOLN), one of India's leading healthcare companies, has reported its operational and financial performance for Q1 FY27 ended June 30, 2026. The company reported consolidated net profit of Rs. 36.23 crore in Q1 FY27 as compared to a net profit of Rs. 27.68 crore reported in Q1 FY26, registering a growth of 30.90 % Y-o-Y. Total income for the quarter ended June 2026 stood at Rs. 201.55 crore, higher by 19.02 % Y-o-Y compared to total income of Rs. 169.34 crore in Q1 FY26. EBITDA for Q1 FY27 stood at Rs. 51.70 crore as compared to EBITDA of Rs. 39.08 crore in Q1 FY26, registering a growth of 32.29 % Y-o-Y. EPS for Q1 FY27 stood at Rs. 18.09 per share.

During FY26, the Company reported net profit of Rs. 87.89 crore (6.74% Y-oY growth), Total income of Rs. 704.48 crore (9.10% Y-o-Y growth), EBITDA of Rs. 131.14 crore (5.78% Y-o-Y growth). Company recommended a dividend of 18 %, Rs. 1.80 per share on the face value of Rs. 10 per share for the FY 2025-26, subject to shareholder approval at the upcoming Annual General Meeting.

LINCOLN PHARMACEUTICALS LTD.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India.
Phone : +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.
Ta. : Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com

WHO - GMP CERTIFIED
Intertek
UKAS

LPL
LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

The Company is targeting revenue of Rs. 1,000 crore over the next three years, as part of its broader strategy to achieve an annual growth rate of 15-18%. The company expects its growth to be supported by strong performance across key therapeutic segments including cardiac, diabetic, dermatology and ENT.

The company is also committed to expanding its global footprint while meeting diverse healthcare needs. CRISIL Ratings has reaffirmed its 'CRISIL A/Stable/CRISIL A1' ratings on Lincoln Pharmaceuticals' bank facilities, reflecting the promoters' strong industry experience, established market position, and healthy financial profile, despite working-capital intensity and regulatory and competitive challenges. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company to 4.60% as on 30 June 2026.

Speaking on the financial performance and future outlook, **Mr. Munjal Patel, Director, Lincoln Pharmaceuticals Ltd**, said, "We have started FY27 with a clear focus on building on our existing growth momentum while strengthening the core areas of our business. We are also evaluating opportunities to expand our reach across domestic territories and international markets, supported by our manufacturing capabilities and product pipeline. With our continued focus on operational efficiency, portfolio expansion and disciplined execution, we remain committed to achieving our medium-term objective of crossing Rs. 1,000 crore in revenue and delivering sustainable growth for our stakeholders while maintaining a debt-free balance sheet."

Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2–3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion.

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.

LINCOLN PHARMACEUTICALS LTD.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.
Ta. : Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com

WHO - GMP CERTIFIED
Intertek
UKAS

LINCOLN
PHARMACEUTICALS LTD.
HEALTHCARE FOR ALL

Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has over 1,700 registered products and another 700 in pipeline. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with vision for nurturing innovations and bringing them to Indian patients at affordable cost to create **"Healthcare for All".**

Lincoln Pharma has two state-of-the-art manufacturing facility units at Khatraj in Ahmedabad and Mehsana, Gujarat. Company's manufacturing facilities comply with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018, other ROW and emerging market regulatory approvals. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D facility of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600. Company has a wide national distribution network through 21+ Super Stockist in 26 states across India.

Going green, company has also set up a new Solar Plant at Mehsana factory and Khatraj factory in addition to at Radhanpur, Gujarat and two windmills. This way we are nearly a 100% green renewable energy consuming company resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi
DSNN Consultancy
9099030184
gopal@dsnnconsultancy.com

LINCOLN PHARMACEUTICALS LTD.

Darshit A. Shah (CFO)
Lincoln Pharmaceuticals Ltd
+91-79-4107- 8048
darshit@lincolnpharma.com